Tri-zidine M modified release tablets p/o 35mg №10×6

Name:
Tri-zidine M tablets with MB p/o 35 mg in a cell. pack No. 10×6
Description:
Film-coated tablets, pink, with a biconvex surface. The main active ingredient Trimetazidine Release form Modified release tablets, film-coated, 35 mg. Dosage 35 mg Special instructions and precautions The drug is not intended for the relief of angina attacks and is not indicated for the initial course of therapy for unstable angina or myocardial infarction, as well as in preparation for hospitalization or in its first days. In an angina attack, coronary pathology should be reassessed and the treatment used adjusted (medication and possibly revascularization). Trimetazidine can cause or worsen the symptoms of parkinsonism (tremor, akinesia, increased muscle tone), the patient should be monitored regularly, especially the elderly patient. In doubtful cases, the patient should be referred to a neurologist for an appropriate examination. The development of movement disorders, such as symptoms of parkinsonism, tremor, restless legs syndrome, unsteadiness when walking, may lead to the final decision to cancel trimetazidine. The frequency of development of motor disorders is low. It is usually reversible and resolves upon discontinuation of trimetazidine. In most cases, after stopping trimetazidine, patients recovered within 4 months. If the symptoms of parkinsonism persisted for more than 4 months after the withdrawal of trimetazidine, a consultation with a neurologist is necessary. With unsteady walking or low muscle tone, the patient may fall, especially when using antihypertensive drugs. It should be taken with caution if patients may experience an increase in trimetazidine excretion time from the body: moderate renal impairment; elderly patients over 75 years of age. first line funds. Method of administration and doses For oral administration. Tablets should be swallowed whole with water. Take 1 tablet (35 mg) 2 times a day – in the morning and in the evening – with meals. Patients with impaired renal function For patients with moderate renal impairment (creatinine clearance 30-60 ml / min), it is recommended to take one tablet (35 mg) in the morning with food. Elderly Patients In elderly patients, the elimination time of trimetazidine from the body is increased due to reduced renal function. For patients with moderate renal impairment (creatinine clearance 30-60 ml/min), it is recommended to take a 35 mg tablet in the morning with meals. The dose should be titrated with caution. The duration of the course of treatment is determined by the doctor. The result of treatment should be evaluated after three months and in the absence of a response to treatment, the drug should be discontinued. Use during pregnancy and lactation In animal experiments, a teratogenic effect has not been detected, however, due to the lack of clinical data, the appointment of this drug during pregnancy should be avoided. Treatment with the drug is not recommended during breastfeeding, because. There are no data on the excretion of trimetazidine in breast milk. Use in children The safety and efficacy of trimetazidine in children under 18 years of age has not been established. Influence on the ability to drive vehicles and control mechanisms In clinical trials, it was found that trimetazidine does not have a hemodynamic effect. However, during post-registration monitoring, dizziness and drowsiness were observed in patients, which may affect the ability to drive a car. Interaction with other drugs No interactions with other medicinal products have been noted. Contraindications Hypersensitivity to trimetazidine or any of the excipients. Parkinson’s disease, parkinsonian symptoms, tremors, restless leg syndrome and other movement disorders. Severe renal impairment (creatinine clearance <30 ml/min). Each tablet contains: trimetazidine dihydrochloride - 35 mg iron oxide red (E172), iron oxide black (E172)). Overdose There is limited information on overdose with trimetazidine. Treatment should be symptomatic. Side effectsNervous system: often - dizziness, headache; frequency unknown - symptoms of parkinsonism (tremor, akinesia, increased muscle tone), restless legs syndrome, unsteadiness when walking and other motor disorders, usually reversible, resolved when trimetazidine was discontinued. Sleep disturbance (drowsiness, insomnia). Cardiovascular diseases: rarely - palpitations; extrasystole; tachycardia; arterial hypotension; orthostatic hypotension, which may be associated with malaise, dizziness, or falling, especially in patients taking antihypertensive treatment; hyperemia. Gastrointestinal diseases: often - abdominal pain, diarrhea, dyspepsia, nausea, vomiting; frequency unknown - constipation. Skin and subcutaneous tissue: often - rash, itching, urticaria; frequency unknown - acute generalized exanthematous pustulosis, Quincke's edema. General disorders: often - asthenia. Blood and lymphatic system: the frequency is unknown - agranulocytosis, thrombocytopenia, thrombocytopenic purpura. Hepatobiliary system: frequency unknown - hepatitis. Storage conditions In a place protected from moisture at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Tri-zidine M modified release tablets po 35mg #10x6 Price of Tri-zidine M modified release tablets po 35mg #10x6